Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
Current Used Vehicle Market Conditions: Q2 2020
Building on a May rebound, wholesale prices in June rose by nearly 10% month-over-month.
Cracking the Code: What DTCs Tell Us About Vehicle Repair Trends
Diagnostic scanning has become a critical first—and last—step in the repair process. While mechanics have long relied on it to identify emission system malfunctions, collision repairers are now more routinely performing pre- and post-scans.
At the eye of the storm: An opioid overdose epidemic and a viral pandemic converge
s 2020 opened, a persistent and tragic opioid overdose epidemic was near the front of a list of national concerns in the US. Some 20+ million Americans are reported to have a substance use disorder and 2M of those misuse opioids.
Is Your Workplace Safe2Work?
As employers are looking for efficient ways to keep work environments safe from COVID-19, Optis has developed Safe2Work, an app-enabled, web-based
Quality Control in Clinical, Interview with Sharon Riley
We interviewed Sharon Riley, Director of Service Operations for Field Case Management, Coventry about best practices for quality assurance within a clinical case management program. Read on for her insightful responses.
Opioid Risk Mitigation: Medication-Assisted Treatment (MAT) and Naloxone
This week in our in-depth review of our Coventry Drug Trends series, part three, we focus on opioid risk mitigation strategies. While opioids continue to decline in workers’ compensation as both a percentage of total script volume and costs, it remains vital to promote evidence-based strategies such as MAT and naloxone to curb opioid issues.